Investigational drug · Phase 3
Decartes-08
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myasthaenia Gravis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Decartes-08"
First trial start
2025
May 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Decartes-08", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myasthaenia Gravis
Largest trials
Live from ClinicalTrials.gov: studies naming "Decartes-08" as an intervention, largest first.
- Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisPivotal-lookingActive, not recruiting
Cartesian TherapeuticsIndustry
NCT06799247 · 128 participants · Start May 6, 2025 · Primary completion Dec 30, 2026
Drug: Decartes-08 · For: Myasthaenia Gravis
Sites: Tucson, Arizona; Carlsbad, California; Los Angeles, California · 34 sites in all
- Descartes-08 in Autoantibody MyositisRecruiting
Cartesian TherapeuticsIndustry
NCT07391605 · 60 participants (planned) · Start Apr 28, 2026 · Primary completion Nov 2027
Drug: Descartes-08 · For: Antisynthetase Syndrome
Sites: Orange, California; Boston, Massachusetts; Chapel Hill, North Carolina · 4 sites in all
Cartesian TherapeuticsIndustry
NCT07089121 · 50 participants (planned) · Start Jan 14, 2026 · Primary completion Dec 2027
Drug: Descartes-08 · For: Childhood-onset Systemic Lupus Erythematous; ANCA-Associated Vasculitis (AAV); Juvenile Myasthenia Gravis and 1 more
Sites: Washington D.C., District of Columbia; St Louis, Missouri; Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.